On January 20, Core Medical received the “Clinical Trial Approval Opinion Sheet” approved and issued by the Medical Device Technology Review Center of the State Drug Administration, and approved the Corheart 6 implantable left ventricular assist system to conduct clinical trials.
Core medical has received nearly 100 million yuan of investment, and Shenzhen’s “China Heart” technology has made another breakthrough
In October 2020, Shenzhen Core Medical Technology Co., Ltd. (hereinafter referred to as “Core Medical”) received nearly 100 million yuan in Series A financing, led by Lianxin Capital, Puhua Capital and Yifeng Capital.